Chugai Seiyaku Kabushiki Kaisha

Zeon Corporation

Nec Corporation

Kyorin Seiyaku Kabushiki Kaisha

Kyorin Pharmaceutical Co., Ltd.

Hiroshi Koga

Haruhiko Sato

Hiroyuki Nabata

Masanobu Sato

Takenori Ishizawa

Takashi Dan

Tsutomu Irikura

Takashi Mori

Akira Ito

Etsuro Onuma

Michitaka Akima

Hisanori Takanashi

Tsutomu Sato

Yasuhiro Wakizaka

Kouichirou Maeda

Keiichiro Tanaka

Seigo Suzue

Koji Annaka

Satoshi Murayama

Masuhiro Oonishi

Masuhiro Onishi

Eiji Kumagai

Provided is a method that enables efficient production of a laminate for a secondary battery including an electrode and a separator that are affixed to each other while also ensuring adhesive strength between the electrode and the separator. The method of producing a laminate for a secondary battery includes: a step (A) of forming an adhesive material on an affixing surface of at least one of an electrode and a separator; a step (B) of, after step (A), conveying the electrode and the separator to an affixing start position without bringing another member into contact with the affixing surface on which the adhesive material has been formed; and a step (C) of, after step (B), affixing the electrode and the separator to each other via the affixing surface. The formed amount of the adhesive material in step (A) is not less than 0.1 g/mand not more than 100 g/m.

Method of producing laminate for secondary battery

Provided is a composition for a non-aqueous secondary battery adhesive layer containing organic particles, a thixotropic agent, and water. The organic particles have a core-shell structure including a core portion and a shell portion at least partially covering an outer surface of the core portion. The composition for a non-aqueous secondary battery adhesive layer has a viscosity &#x3b7;at a shear rate of 100 sof less than 10 mPa&#xb7;s, a viscosity &#x3b7;at a shear rate of 10,000 sof not less than 0.5 mPa&#xb7;s and not more than 2.4 mPa&#xb7;s, and a ratio (&#x3b7;/&#x3b7;) of the viscosity &#x3b7;relative to the viscosity &#x3b7;of not less than 1.2 and not more than 10.

Composition for non-aqueous secondary battery adhesive layer, battery member for non-aqueous secondary battery and method of producing same, method of producing laminate for non-aqueous secondary battery, and method of producing non-aqueous secondary battery

Provided is a laminate for a non-aqueous secondary battery that, in transfer of a functional layer onto a substrate for a non-aqueous secondary battery, enables easy peeling of the functional layer from a releasable substrate while also enabling good adhesion of the functional layer to the substrate for a non-aqueous secondary battery. The laminate for a non-aqueous secondary battery includes a releasable substrate and a functional layer containing a binder. The functional layer is formed in a dotted form on a surface A at one side of the releasable substrate.

Laminate for non-aqueous secondary battery and method of producing same, roll for non-aqueous secondary battery, and method of producing non-aqueous secondary battery component

Provided is a technique relating to a slurry for a non-aqueous secondary battery that can stably be applied onto a battery member surface even in a situation in which an inkjet method is adopted. A method of producing the slurry for a non-aqueous secondary battery includes a degassing step of reducing the dissolved carbon dioxide gas concentration of a mixture containing a particulate polymer (A) and water.

Slurry for non-aqueous secondary battery and method of producing same, battery member for non-aqueous secondary battery and method of producing same, and non-aqueous secondary battery

Remedies for peripheral circulation disturbances

An agent for treating or ameliorating diabetic complications which contains at least one potassium channel activator as an active ingredient. The drug is expected to show a therapeutic or ameliorating action on diabetic complications such as retinopathy, neuropathy, nephropathy, peripheral circulation disorders, and skin ulcerations; it also proves effective in preventing, ameliorating, alleviating and gaining recovery from various symptoms and abnormalities caused by those diseases, as exemplified by blindness, proteinurea, pain, numbness, psychroesthesia, intermittent claudication and gangrene.

Therapeutics for diabetic complications

A logic circuit which is driven at low voltage and operates at high speed and low power consumption is provided. Substrate potentials of P and N type transistors MP,and MN,constituting an inverter are controlled correspondingly to a stable state of the inverter. In a stable state of the inverter in which the P type transistor MP,is ON, the substrate potential of the N type transistor MN,which is OFF is lowered to ground potential or lower and, in a stable state of the inverter in which the N type transistor MN,is ON, the substrate potential of the P type transistor MP,which is OFF is raised to a power source potential or higher.

Logic circuit having reduced power consumption

Novel benzopyran and benzoxazine derivatives represented by the general formula: wherein R.sub.1 and R.sub.2 represent a lower haloalkyl group, R.sub.3 represents a hydrogen atom, etc., R.sub.4 represents a heterocyclic group or A--O-- wherein A represents a cyclic structure, etc., R.sub.5 and R.sub.6 represent a lower haloalkyl, X represents .dbd.N--, N.fwdarw.O, etc, are disclosed. These compounds exhibit K.sup.+ channel opening activating and can be widely used as an anti-asthma drug, an anti-epilepsy drug, etc.

Benzopyran and benzoxazine derivatives

Novel benzopyran and benzoxazine derivatives represented by the general formula: ##STR1## wherein R.sub.1 and R.sub.2 represent a lower haloalkyl group, R.sub.3 represents a hydrogen atom, etc., R.sub.4 represents a heterocyclic group or A--O-- wherein A represents a cyclic structure, etc., R.sub.5 and R.sub.6 represent a lower haloalkyl, X represents .dbd.N--, N.fwdarw.O, etc, are disclosed. These compounds exhibit K.sup.+ channel opening activating and can be widely used as an anti-asthma drug, an anti-epilepsy drug, etc.

Benzopyran derivatives

Erythromycin derivatives

N-(2-cyanoethyl)-6-fluoroalkyl-2h-1-benzopyran derivatives

An amplifier circuit configured to be selectively brought into an active condition or in an inactive condition by a control signal, comprises an input differential circuit stage having a pair of input terminals and one output node, and an output emitter follower stage having a driving NPN transistor having a base connected to the output node and a collector connected to a high voltage Vcc. An emitter of the driving NPN transistor is connected to an output terminal and a collector of an active load NPN transistor having an emitter connected to a low voltage Vss. A control circuit is connected to a base of the active load NPN transistor and is controlled by the control signal so as to turn on the active load NPN transistor in response to an active control signal and to turn off the active load NPN transistor in response to an inactive control signal. Another control circuit is connected to the base of the driving transistor and controlled by the control signal so as to cut off a base current of the driving transistor in synchronism with the inactive control signal.

Differential amplifier having output stage quickly brought into inactive

Growing community of inventors

Tokyo, Japan

Hiroshi Koga